August 18, 2025 — Leads & Copy — Cantargia (STO:CANTA) has appointed Dr. Hilde Steineger, a biotechnology executive, as its new CEO, effective September 1. Dr. Steineger previously served as Co-Founder and COO of NorthSea Therapeutics and CEO of Staten Biotechnology, where she led a $480M deal with Novo Nordisk.
According to Cantargia, Dr. Steineger’s experience includes financial analysis, venture capital, and business development. Damian Marron, the current Interim CEO, will remain on the Cantargia Board. Dr. Steineger also served as Head of Strategic Innovation Management in Nutrition and Health Division (EN) of BASF. She has prior extensive experience in the intersection of business/finance and life science, both as a financial analyst covering life science stocks, as venture capitalist at a life science venture fund and as Head of Business Development at Pronova BioPharma.
Dr. Magnus Persson, Chairman of the Board of Directors, stated Dr. Steineger’s appointment is a natural development as the company matures, especially with two product candidates in clinical trials and a recent transaction with an international pharmaceutical company. Damian Marron, Interim Chief Executive Officer, said it has been a privilege and a pleasure to have had the opportunity to lead Cantargia over the last seven months.
Magnus Persson, Chairman, can be reached at info@cantargia.com.
Cantargia AB (publ) develops antibody-based treatments for life-threatening diseases. The company’s oncology program, nadunolimab (CAN04), is being studied clinically in combination with chemotherapy, focusing on pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia’s second development program, CAN10, addresses the treatment of serious autoimmune/inflammatory diseases. Cantargia has an agreement with Otsuka Pharmaceuticals on the acquisition of the CAN10 program.
Source: Cantargia
